C(SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(O)(=O)OP(O)(=O)O[CH2:21][C@H:22]1O[C@@H:25]([N:27]2[C:36]3N=CN=[C:31](N)[C:30]=3N=C2)[C@H:24](O)[C@@H:23]1OP(O)(O)=O)(=O)C.Cl.NCC[C:56]1[C:64]2[C:59](=CC=CC=2)[NH:58][CH:57]=1.CCNC(CCNC([C@H](O)C(COP(OP(OC[C@H]1O[C@@H](N2C3N=CN=C(N)C=3N=C2)[C@H](O)[C@@H]1OP(O)(O)=O)(O)=O)(O)=O)(C)C)=O)=[O:69].C1C(SSC2C=CC([N+]([O-])=O)=C(C(O)=O)C=2)=CC(C(O)=O)=C([N+]([O-])=O)C=1.P([O-])([O-])([O-])=O.[Na+].[Na+].[Na+].SC[C@H]([C@@H](CS)O)O.C(N(CC(O)=O)CC(O)=O)CN(CC(O)=O)CC(O)=O.C1C=CC2NC=C(CCO)C=2C=1.C[14C](SCCNC(CCNC([C@H](O)C(COP(OP(OC[C@H]1O[C@@H](N2C3N=CN=C(N)C=3N=C2)[C@H](O)[C@@H]1OP(O)(O)=O)(O)=O)(O)=O)(C)C)=O)=O)=O.C(OC(=O)C)(=O)C>C(N(CC)CC)C>[C:59]([NH:58][CH2:57][CH2:56][C:24]1[C:23]2[C:36](=[CH:30][CH:31]=[CH:21][CH:22]=2)[NH:27][CH:25]=1)(=[O:69])[CH3:64]The following were purchased: acetyl-CoA (Pharmacia Biotech Inc.); tryptamine-HCl, desulfo-CoA, glutathione-agarose, DTNB (Sigma); sodium phosphate, dithiothreitol, guanidinium-HCl, EDTA (Fisher Scientific); tryptophol (Aldrich); and [14C]acetyl-CoA (60 Ci/mol) (NEN Life Science Products). N-acetyltryptamine was synthesized by reacting tryptamine-HCl (500 mg, 2.5 mmol) with acetic anhydride (260 mg, 2.5 mmol) in the presence of excess triethylamine (1.75 ml). After vigorous stirring at room temperature for 50 min, the mixture was partitioned between ethyl acetate (80 ml) and water (70 ml). The organic phase was washed with saturated aqueous NaHCO3 (50 ml), 0.1 M HCl (50 ml), Na2SO4 (anhydride), and the resultant was concentrated in vacuo to afford N-acetyltryptamine as off-white crystals (88% yield). Purity (>95%) was established by TLC and 1H NMR.